Chlorodehydromethyltestosterone (4-chloro-17α-methyl-androst-1,4-dien-3-one-17β-ol) is a modified form of Dianabol, developed in 1961 by Jenapharm in East Germany. The addition of a 4-chloro group to the Dianabol backbone eliminates aromatization entirely while preserving meaningful anabolic activity. This compound became central to the German Democratic Republic's systematic athletic enhancement program (State Plan 14.25), where it was administered to thousands of athletes across virtually every Olympic discipline — valued precisely for its ability to improve performance without the telltale signs of water retention.

Turinabol binds the androgen receptor with moderate affinity and promotes nitrogen retention and protein synthesis at a steady, controlled rate. Because it does not aromatize, there is zero estrogenic activity — no water retention, no bloating, no gynecomastia risk. Its anabolic:androgenic ratio is approximately 54:6 (relative to methyltestosterone), which means it produces lean gains with exceptionally low androgenic side effects. The compound also reduces SHBG, amplifying the bioavailability of other androgens when used in a stack.

Turinabol is the "patience compound." It does not deliver the explosive mass of Anadrol or the rapid cosmetic transformation of Winstrol. What it offers is steady, retainable lean tissue accrual, reliable strength progression, and a clean physiological profile. The muscle gained on Turinabol is lean and dense — there is minimal post-cycle loss because there is no water component to shed. Athletic researchers value it for endurance and recovery improvements that do not raise suspicion via sudden weight changes.

This compound is well-suited for novice and intermediate researchers. Its low androgenic load makes it one of the more tolerable orals available, and its absence of estrogenic effects simplifies on-cycle management. Female researchers can use it at conservative dosages (5–10 mg daily) with lower virilization risk than most alternatives. It pairs naturally with a Testosterone base and stacks well with injectable compounds like Equipoise or Primobolan for lean-gain protocols.

Turinabol has a half-life of approximately 16 hours, allowing for once-daily dosing, though splitting the dose into two administrations can provide slightly more stable blood levels. Typical research dosages are 20–50 mg daily for males. As a 17-alpha-alkylated compound, it does carry hepatotoxicity — though less than Dianabol or Anadrol. Liver-support supplementation is recommended, and cycle lengths should be limited to 6–8 weeks. The most commonly reported side effect beyond liver stress is suppression of endogenous testosterone production, which necessitates a proper PCT protocol.